# Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

> **NCT05698199** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Immunomic Therapeutics, Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** ITI-1001

## Key facts

- **NCT ID:** NCT05698199
- **Lead sponsor:** Immunomic Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-21
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05698199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05698199, "Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05698199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*